Nuclear androgen receptor assay in biopsy‐size specimens of human prostatic tissue

Blankenstein, M.A.; Bolt-deVries, Joan; Foekens, John A.

doi:10.1002/pros.2990030405

Cited by 19 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have observed that the performance of the protamine sulphate assay [18] and the nuclear androgen receptor content of BPH (Fig. 4, upper panel) are independent on the protein content of the sample.…”

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

Nuclear Androgen Receptor Content in Biopsy Specimens From Histologically Normal, Hyperplastic, and Cancerous Human Prostatic Tissue

et al. 1985

View full text Add to dashboard Cite

Androgen receptors (ARn) were assayed in nuclear extracts of prostatic biopsies from 60 patients with benign prostatic hyperplasia (BPH) and 82 patients with prostatic cancer (PC), with an exchange assay using heparin extraction, labelling with 3H-R1881, and protamine sulphate precipitation. The content of ARn of BPH biopsies (38 f 34 fmol/mg protein [mean f SD]; n = 70) was not different from that of PC biopsies (39 f 32 fmol/mg protein; n = 115). Biopsies showing essentially normal prostatic tissue had a lower ARn content (12 f 13 fmoUmg protein; n = 6). The content of ARn was independent of the age of the patient and of the histological grade of the carcinomas. A considerable variation in ARn content within tumors of individual patients was found, indicating that ARn are not uniformly distributed over prostatic tissue; ie, cells with high and low receptor content may coexist in different proportions in different regions of the prostate. Therefore, assays on multiple biopsies may be required for a proper estimation of the mean receptor content. The question remains, however, whether the behavior of the tumor is adequately predicted by the mean receptor level or, for instance, by the region with the lowest receptor content.

show abstract

Section: Discussionmentioning

confidence: 84%

“…A method for the estimation of nuclear androgen receptors has been published [15], and recently this method has been made applicable to biopsy specimens [18]. Using relatively large samples ( -200 mg) differences have been shown in the nuclear androgen receptor content of normal and pathologic human prostatic tissue [19,20].…”

Section: Introductionmentioning

confidence: 99%

Nuclear Androgen Receptor Content in Biopsy Specimens From Histologically Normal, Hyperplastic, and Cancerous Human Prostatic Tissue

et al. 1985

View full text Add to dashboard Cite

show abstract

“…Their studies indicate lack of correlation between receptor site content of 50 mg and 500 mg tissue specimens from the same prostate gland. 29 In a report which appeared during the preparation of this manuscript, these investigators described significant variation in nuclear receptor site content of biopsy size tissue specimens from the same pr~state. '~ In this latter study, content was primarily measured using single determinations.…”

Section: Discussionmentioning

confidence: 99%

Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation to prognostic significance of receptor measurements for survival of advanced cancer patients

Gorelic

Lamm

Ramzy

et al. 1987

Cancer

View full text Add to dashboard Cite

Needle biopsy specimens of primary adenocarcinoma and surgical specimens of carcinomatous nodal tissue were obtained from previously untreated clinical D stage prostatic adenocarcinoma patients. Assessment of the relation between specimen androgen receptor site content and survival using either scatterplots or Kaplan-Meier analyses showed specimen receptor content was a poor prognostic P > 0.1, of survival subsequent to orchiectomy or diethylstilbestrol (DES) therapy. The possibility that hetero-geneity of specimen androgen receptor site content contributed to this finding was evaluated by comparing receptor content of multiple small or large tissue specimens from the same prostate gland of patients with benign prostatic hyperplasia or nonmetastatic prostatic cancer. This evaluation showed significant microheterogeneity of human prostate androgen receptor site content which was substantially masked in large tissue specimens. We conclude that microheterogeneity of human prostate androgen receptor site content compromises the use of biopsy specimen androgen receptor measurements as a prognostic of patient survival subsequent to initiation of hormonal therapy.

show abstract

“…For the receptor assay used in the present study it has been shown that the mean ARn content was not dependent on the amount of tissue used (25 mg, 50 mg, 100 mg, 500 mg). We have previously reported on the validity of this single-point assay for homogenized tissue pools [5]. For actual needle biopsies a large variation in receptor values in the same tumor was found.…”

Section: Discussionmentioning

confidence: 91%

Prediction of time to progression after orchiectomy by the nuclear androgen receptor content from multiple biopsy specimens in patients with advanced prostate cancer

et al. 1988

Self Cite

View full text Add to dashboard Cite

The nuclear androgen receptor (ARn) content of cancerous prostatic tissue has been investigated as a prognosticator for time to progression under endocrine therapy. In 1981 a prospective study was started to investigate whether the ARn content in biopsy specimens of patients with prostatic carcinoma predicts the duration of response following hormonal treatment. ARn was estimated by a microassay which involves extraction of nuclear pellets with a heparin-containing buffer, exchange labeling of the nuclear extract with 3H-R1881, and quantitation of the receptor with protamine sulphate precipitation. One hundred and fifteen patients with prostatic cancer entered this study; 47 patients had evidence of metastatic disease as proven by bone scan. Forty-two patients were treated by orchiectomy; 37 of these patients are evaluable with a minimal follow-up of 30 months. A relationship between the nuclear androgen receptor content and the time to progression following orchiectomy in these patients with metastatic disease of the prostate was not found. This could possibly be attributed to the heterogeneous nature of the prostatic tumor tissue with respect to the distribution of the ARn. We conclude that androgen receptor assay in needle biopsies, at least in this study, had no value for the prediction of the time to progression after orchiectomy.

show abstract

Nuclear androgen receptor assay in biopsy‐size specimens of human prostatic tissue

Cited by 19 publications

References 10 publications

Nuclear Androgen Receptor Content in Biopsy Specimens From Histologically Normal, Hyperplastic, and Cancerous Human Prostatic Tissue

Nuclear Androgen Receptor Content in Biopsy Specimens From Histologically Normal, Hyperplastic, and Cancerous Human Prostatic Tissue

Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation to prognostic significance of receptor measurements for survival of advanced cancer patients

Prediction of time to progression after orchiectomy by the nuclear androgen receptor content from multiple biopsy specimens in patients with advanced prostate cancer

Contact Info

Product

Resources

About